source
- Scribe Therapeutics upsizes IPO to $128.7 million to fund lipid-lowering gene therapyScribe Therapeutics announced pricing its initial public offering at $128.7 million, surpassing the $96 million target it had set earlier in the week. The company sold 8.6 million shares at $15 ea…
- Scribe Therapeutics raises $129 million in gene-editing IPO, debuting on NasdaqScribe Therapeutics completed an initial public offering that raised close to $129 million. The company sold 8.58 million shares at $15 each and will trade on Nasdaq under the ticker SCTX. The off…